Clin Endosc.  2014 Jan;47(1):40-46.

Barrett Esophagus: When to Endoscope

Affiliations
  • 1Division of Gastroenterology, The Centre for Therapeutic Endoscopy and Endoscopic Oncology, St. Michael's Hospital, Toronto, ON, Canada. kandelg@smh.ca

Abstract

Increasing interest in identifying an effective strategy for decreasing the burden of esophageal adenocarcinoma (EAC) has been fuelled by the rising EAC rates worldwide, the morbidity associated with esophagectomy, and the development of endoscopic methods for curing early-stage EAC. In the face of this enthusiasm, however, we should be cautious about continuing our current evidence-free approach to screening and one with unclear benefits and unclear costs to the community. The literature is increasingly recognizing that the value of traditional endoscopy for screening and surveillance of Barrett esophagus may be more limited than initially believed. A better understanding of the risk factors for Barrett esophagus and progression to dysplasia and a more individualized risk calculation will be useful in defining populations to consider for Barrett screening. The development of novel, nonendoscopic screening techniques and of less expensive endoscopic techniques holds promise for a cost-effective screening and surveillance method to curtail the increasing rates of EAC.

Keyword

Barrett esophagus; Endoscopy; Mass screening; Epidemiology

MeSH Terms

Adenocarcinoma
Barrett Esophagus*
Endoscopes*
Endoscopy
Epidemiology
Esophagectomy
Mass Screening
Methods
Risk Factors

Reference

1. Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett'S esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013; 145:312–319. PMID: 23673354.
Article
2. Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett'S esophagus compared with the general population: a population-based cohort study. Gastroenterology. 2013; 144:1375–1383. PMID: 23583429.
Article
3. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett'S adenocarcinomas: a population-based study. Gastroenterology. 2002; 122:633–640. PMID: 11874995.
Article
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–2917. PMID: 21351269.
Article
5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003; 349:2241–2252. PMID: 14657432.
Article
6. Lao-Sirieix P, Fitzgerald RC. Screening for oesophageal cancer. Nat Rev Clin Oncol. 2012; 9:278–287. PMID: 22430857.
Article
7. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013; 381:400–412. PMID: 23374478.
Article
8. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998; 339:1979–1984. PMID: 9869669.
Article
9. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002; 359:1727–1733. PMID: 12049861.
10. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355:11–20. PMID: 16822992.
Article
11. Pennathur A, Farkas A, Krasinskas AM, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg. 2009; 87:1048–1054. PMID: 19324126.
Article
12. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013; 19:5598–5606. PMID: 24039351.
Article
13. Umar SB, Fleischer DE. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol. 2008; 5:517–526. PMID: 18679388.
Article
14. Oze I, Matsuo K, Wakai K, et al. Alcohol drinking and esophageal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2011; 41:677–692. PMID: 21430021.
Article
15. Lin J, Zeng R, Cao W, Luo R, Chen J, Lin Y. Hot beverage and food intake and esophageal cancer in southern China. Asian Pac J Cancer Prev. 2011; 12:2189–2192. PMID: 22296354.
16. Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008; 122:1118–1129. PMID: 17990321.
Article
17. Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008; 103:2694–2699. PMID: 18853967.
Article
18. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97:142–146. PMID: 15657344.
Article
19. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998; 83:2049–2053. PMID: 9827707.
Article
20. Armstrong RW, Borman B. Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978-1992. Int J Epidemiol. 1996; 25:941–947. PMID: 8921478.
Article
21. Stavrou EP, McElroy HJ, Baker DF, Smith G, Bishop JF. Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972-2005. Med J Aust. 2009; 191:310–314. PMID: 19769552.
Article
22. Edgren G, Adami HO, Weiderpass Vainio E, Nyrén O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013; 62:1406–1414. PMID: 22917659.
Article
23. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. The molecular biology of esophageal adenocarcinoma. J Surg Oncol. 2005; 92:169–190. PMID: 16299787.
Article
24. Jenkins GJ, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg. 2002; 89:824–837. PMID: 12081731.
Article
25. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010; 10:87–101. PMID: 20094044.
Article
26. Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008; 1:329–338. PMID: 19138977.
Article
27. Rajendra S. Barrett's oesophagus in Asians: are ethnic differences due to genes or the environment? J Intern Med. 2011; 270:421–427. PMID: 21575083.
28. Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007; 13:1585–1594. PMID: 17461453.
Article
29. Lagergren J, Bergström R, Lindgren A, Nyérn O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340:825–831. PMID: 10080844.
Article
30. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003; 95:1404–1413. PMID: 13130116.
Article
31. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968; 65:281–393. PMID: 4234760.
32. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005; 129:1825–1831. PMID: 16344051.
Article
33. Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ. 2010; 341:c4372. PMID: 20833740.
Article
34. Rubenstein JH, Mattek N, Eisen G. Age- and sex-specific yield of Barrett's esophagus by endoscopy indication. Gastrointest Endosc. 2010; 71:21–27. PMID: 19748616.
Article
35. Rajendra S, Kutty K, Karim N. Ethnic differences in the prevalence of endoscopic esophagitis and Barrett's esophagus: the long and short of it all. Dig Dis Sci. 2004; 49:237–242. PMID: 15104363.
Article
36. Kim JY, Kim YS, Jung MK, et al. Prevalence of Barrett's esophagus in Korea. J Gastroenterol Hepatol. 2005; 20:633–636. PMID: 15836715.
Article
37. Azuma N, Endo T, Arimura Y, et al. Prevalence of Barrett's esophagus and expression of mucin antigens detected by a panel of monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma in Japan. J Gastroenterol. 2000; 35:583–592. PMID: 10955596.
Article
38. Yoo SS, Lee WH, Ha J, et al. The prevalence of esophageal disorders in the subjects examined for health screening. Korean J Gastroenterol. 2007; 50:306–312. PMID: 18159162.
39. Choi CY, Suh S, Park JS, et al. The prevalence of Barrett's esophagus and the comparison of Barrett's esophagus with cardiac intestinal metaplasia in the health screening at a secondary care hospital. Korean J Gastroenterol. 2012; 60:219–223. PMID: 23089907.
Article
40. Park JJ, Kim JW, Kim HJ, et al. The prevalence of and risk factors for Barrett's esophagus in a Korean population: a nationwide multicenter prospective study. J Clin Gastroenterol. 2009; 43:907–914. PMID: 19417682.
41. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000; 119:333–338. PMID: 10930368.
Article
42. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003; 138:176–186. PMID: 12558356.
Article
43. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 2012; 61:970–976. PMID: 21997553.
Article
44. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011; 103:1049–1057. PMID: 21680910.
Article
45. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011; 365:1375–1383. PMID: 21995385.
Article
46. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut. 2010; 59:1030–1036. PMID: 20639249.
Article
47. Sikkema M, Looman CW, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol. 2011; 106:1231–1238. PMID: 21577245.
48. Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010; 105:1523–1530. PMID: 20461069.
Article
49. Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology. 2011; 141:1179–1186. PMID: 21723218.
Article
50. Coleman HG, Bhat S, Johnston BT, McManus D, Gavin AT, Murray LJ. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. Gastroenterology. 2012; 142:233–240. PMID: 22062359.
Article
51. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008; 67:394–398. PMID: 18045592.
Article
52. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009; 360:2277–2288. PMID: 19474425.
53. Park CH. Proposal of a screening program for gastric cancer in Korea. J Korean Med Assoc. 2002; 45:964–971.
Article
54. Cho E, Kang MH, Choi KS, Suh M, Jun JK, Park EC. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev. 2013; 14:2533–2540. PMID: 23725170.
Article
55. Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology. 2013; 144:62–73. PMID: 23041329.
Article
56. American Gastroenterological Association. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011; 140:1084–1091. PMID: 21376940.
Article
57. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther. 2010; 32:1222–1227. PMID: 20955441.
Article
58. Rubenstein JH, Morgenstern H, Appelman H, et al. Prediction of Barrett's esophagus among men. Am J Gastroenterol. 2013; 108:353–362. PMID: 23318485.
Article
59. Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013; 108:915–922. PMID: 23567358.
Article
60. Jobe BA, Hunter JG, Chang EY, et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. Am J Gastroenterol. 2006; 101:2693–2703. PMID: 17227516.
Article
61. Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2009; 104:1533–1539. PMID: 19491867.
Article
62. Lao-Sirieix P, Boussioutas A, Kadri SR, et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut. 2009; 58:1451–1459. PMID: 19651633.
Article
63. Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012; 157:808–816. PMID: 23208168.
Article
64. ASGE Standards of Practice Committee. Evans JA, Early DS, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012; 76:1087–1094. PMID: 23164510.
Article
Full Text Links
  • CE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr